Grocela J A, McDougal W S
Department of Urology, Harvard Medical School, Boston, Massachusetts, USA.
Urol Clin North Am. 2000 Feb;27(1):47-51, viii. doi: 10.1016/s0094-0143(05)70233-0.
This article examines the Nuclear Matrix Protein (NMP22) urine test for recurrent bladder cancer detection. Studies with NMP22 are compared to cytology for sensitivity and specificity. False positives and false negatives do occur, and consequences of these are discussed. Speculations are made regarding possible future uses of this test.
